A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance

The emergence of resistance to prostate cancer (PCa) treatment, particularly to androgen deprivation therapy (ADT), has posed a significant challenge in the field of PCa management. Among the therapeutic options for PCa, radiotherapy, chemotherapy, and hormone therapy are commonly used modalities. H...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1395047
Main Authors Xu, Meng-Yao, Xia, Zhi-Yu, Sun, Jian-Xuan, Liu, Chen-Qian, An, Ye, Xu, Jin-Zhou, Zhang, Si-Han, Zhong, Xing-Yu, Zeng, Na, Ma, Si-Yang, He, Hao-Dong, Wang, Shao-Gang, Xia, Qi-Dong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.04.2024
Subjects
Animals
cellular senescence
Cellular Senescence - drug effects
drug resistance
Drug Resistance, Neoplasm
Humans
Immunology
Male
prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
SIPS
treatment resistance
prostate cancer
cellular senescence
drug resistance
SIPS
treatment resistance
Online AccessGet full text

Cover

More Information
Summary:The emergence of resistance to prostate cancer (PCa) treatment, particularly to androgen deprivation therapy (ADT), has posed a significant challenge in the field of PCa management. Among the therapeutic options for PCa, radiotherapy, chemotherapy, and hormone therapy are commonly used modalities. However, these therapeutic approaches, while inducing apoptosis in tumor cells, may also trigger stress-induced premature senescence (SIPS). Cellular senescence, an entropy-driven transition from an ordered to a disordered state, ultimately leading to cell growth arrest, exhibits a dual role in PCa treatment. On one hand, senescent tumor cells may withdraw from the cell cycle, thereby reducing tumor growth rate and exerting a positive effect on treatment. On the other hand, senescent tumor cells may secrete a plethora of cytokines, growth factors and proteases that can affect neighboring tumor cells, thereby exerting a negative impact on treatment. This review explores how radiotherapy, chemotherapy, and hormone therapy trigger SIPS and the nuanced impact of senescent tumor cells on PCa treatment. Additionally, we aim to identify novel therapeutic strategies to overcome resistance in PCa treatment, thereby enhancing patient outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Dechao Feng, University College London, United Kingdom
These authors have contributed equally to this work
These authors have contributed equally to this work and share first authorship
Reviewed by: Bin Xu, Renmin Hospital of Wuhan University, China
Yingkun Xu, Chongqing Medical University, China
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1395047